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Uracil DNA glycosylase interacts 
with the p32 subunit of the replication 
protein A complex to modulate HIV-1 reverse 
transcription for optimal virus dissemination
Cecile Herate1,2,3, Clarisse Vigne1,2,3, Carolin A. Guenzel1,2,3, Marie Lambele1,2,3, Marie‑Christine Rouyez1,2,3 
and Serge Benichou1,2,3*
Abstract 
Background: Through incorporation into virus particles, the HIV‑1 Vpr protein participates in the early steps of the 
virus life cycle by influencing the reverse transcription process. We previously showed that this positive impact on 
reverse transcription was related to Vpr binding to the uracil DNA glycosylase 2 enzyme (UNG2), leading to enhance‑
ment of virus infectivity in established CD4‑positive cell lines via a nonenzymatic mechanism.
Results: We report here that Vpr can form a trimolecular complex with UNG2 and the p32 subunit (RPA32) of the 
replication protein A (RPA) complex and we explore how these cellular proteins can influence virus replication and 
dissemination in the primary target cells of HIV‑1, which express low levels of both proteins. Virus infectivity and 
replication in peripheral blood mononuclear cells and monocyte‑derived macrophages (MDMs), as well as the 
efficiency of the viral DNA synthesis, were significantly reduced when viruses were produced from cells depleted of 
endogenous UNG2 or RPA32. Moreover, viruses produced in macrophages failed to replicate efficiently in UNG2‑ and 
RPA32‑depleted T lymphocytes. Reciprocally, viruses produced in UNG2‑depleted T cells did not replicate efficiently in 
MDMs confirming the positive role of UNG2 for virus dissemination.
Conclusions: Our data show the positive effect of UNG2 and RPA32 on the reverse transcription process leading to 
optimal virus replication and dissemination between the primary target cells of HIV‑1.
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Background
Human immunodeficiency virus type 1 (HIV-1) has 
two main target cells, T CD4-positive lymphocytes and 
myeloid cells, including macrophages and dendritic 
cells. Infection of the CD4-positive T lymphocytes leads 
to the depletion of this cell population during the acute 
phase of the disease while macrophages are identified as 
one of the major reservoirs of virus [1]. HIV-1-infected 
macrophages actively participate in virus dissemination 
and in the establishment of persistent virus reservoirs in 
different host tissues including lungs, gastro-intestinal 
and genital tracts, and the central nervous system (CNS) 
[2, 3]. Strains of HIV-1 have the ability to enter and infect 
different cell types in  vitro and are usually subdivided 
into three main groups according to their co-receptor 
usage. Some viral strains use the beta-chemokine recep-
tor CCR5 (R5 strains) and can infect monocytes and 
macrophages but also PBMCs and primary T lympho-
cytes. Other viral strains, emerging later during the infec-
tion, preferentially enter T lymphocytes and established 
T cell lines via the alpha-chemokine receptor CXCR4 (X4 
strains) and are associated with progression to AIDS (for 
review, [4]). Dual tropic strains with both co-receptor 
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usages also exist and can thus infect all the conventional 
HIV-1 target cells.
Like other viruses, HIV-1 utilizes or perturbs cellular 
pathways in order to optimize essential steps of the virus 
life cycle in T lymphocytes, macrophages or dendritic 
cells. Moreover, the HIV-1 genome contains additional 
genes encoding regulatory proteins Nef, Vif, Vpu and 
Vpr, which are viral factors specialized in hijacking and 
perturbing essential cellular pathways during virus repli-
cation through interactions with host cell proteins. How-
ever, Vpr is the only HIV-1 auxiliary protein specifically 
incorporated into virus particles through direct interac-
tion with the Pr55Gag precursor, since its presence in the 
virion core will be subsequently required during the early 
steps of the virus life cycle in the newly infected cell (for 
review, [5]).
After virus entry, the viral core is released into the 
cytoplasm of the target cell where reverse transcriptase 
synthesizes the viral DNA, and the first role of Vpr is to 
influence the accuracy of the reverse transcription pro-
cess leading to modulation of the mutation rate in the 
newly synthesized viral DNA. Vpr may also contribute 
to the mechanisms that allow the viral DNA to access 
the nuclear compartment. In addition, Vpr is a multi-
functional protein that displays other activities includ-
ing perturbations of the cell cycle progression, induction 
of apoptosis, and transcriptional modulation of host cell 
genes [5].
We and others have previously shown that the role of 
Vpr in the modulation of the reverse transcription pro-
cess is related to the direct interaction and subsequent 
recruitment into virus particles of the nuclear form of 
uracil DNA glycosylase (UNG2) [6–9]. However, the 
specific role of UNG2 incorporation into virions was 
also challenged by other studies [10–12], suggesting that 
UNG2 had either a detrimental [11, 12] or a dispensable 
role in virus replication [10]. UNG2 is a base excision 
repair enzyme mainly involved in removal of uracil resi-
dues from DNA at the replication fork during chromo-
some replication [13]. The inclusion of uracil residues 
in DNA can occur either by mis-incorporation of dUTP 
during replication or by cytosine deamination. UNG2 
is able to bind other key proteins of the DNA repair 
machinery such as the p32 subunit (RPA32) of the rep-
lication protein A complex (RPA), the proliferating cell 
nuclear antigen (PCNA) and the X-ray repair cross-com-
plementing group 1 (XRCC1) [14–20]. The RPA com-
plex is able to bind single-strand DNA (ssDNA) and can 
protect DNA intermediates during DNA replication and 
even stabilize DNA fragments caused by DNA damage 
[21, 22]. Interestingly, it was reported that the RPA com-
plex promotes the recruitment of UNG2 at the replica-
tion fork [21, 22].
UNG2 has been also largely studied for its critical 
role in somatic hypermutation (SHM) and class-switch 
recombination (CSR) at the immunoglobulin locus of 
B lymphocytes [13]. While controversial (for review, 
Refs. [13, 23, 24]), some reports showed that catalyti-
cally inactive mutants of UNG2 were fully proficient in 
CSR in B lymphocytes [25–27] suggesting that the spe-
cific function of UNG2 in CSR was not related to the 
catalytic activity of the protein but depends on a novel 
nonenzymatic function of UNG2. Similarly, we have 
recently reported that the catalytic activity of UNG2 is 
not required for modulation of the HIV-1 reverse tran-
scription process and its positive impact on virus infec-
tivity. This function of UNG2 is related to determinants 
located within the N-terminal region of the protein that 
is required for direct interaction with the RPA32 subu-
nit of the RPA complex [7]. Interestingly, it was recently 
reported that the RPA complex also played a specific role 
during CSR [28].
Here, we report results showing the positive impact 
of UNG2 and RPA32 on the reverse transcription lead-
ing to optimal virus infectivity, replication and dissemi-
nation between HIV-1 primary target cells. Interestingly, 
primary cells such as peripheral blood mononuclear cells 
(PBMCs) and monocyte-derived macrophages express 
low levels of these two cellular proteins.
Results
Vpr, UNG2 and RPA32 can be associated together in a 
trimolecular complex
Previously, we reported that the ability of UNG2 to 
modulate the HIV-1 mutation rate was dependent on a 
60-amino-acid domain located in the N-terminal regula-
tory region (amino acids 30–90) of the cellular protein 
containing the determinants for direct interaction with 
the RPA32 (i.e. p32) subunit of the RPA complex [7] (see 
on Fig.  1d). Therefore, RPA32 expression was shown to 
increase virus infectivity in a single-round infectivity 
assay. In order to further document the role of these two 
cellular proteins in HIV-1 replication, we first evaluated 
whether they could assemble to form a complex with the 
HIV-1 Vpr protein. We used in vitro binding assays per-
formed with recombinant UNG2 and RPA32 expressed in 
E. coli in fusion with the glutathione S-transferase (GST-
UNG2 and GST-RPA32, Fig. 1a, b, respectively). Purified 
recombinant GST-UNG2 and GST-RPA32 were immo-
bilized on glutathione (GSH)-Sepharose beads and then 
incubated with lysates from 293T cells expressing hemag-
glutinin (HA)-tagged forms of Vpr, UNG2 and RPA32, 
either alone or in combination. Bound proteins were then 
analyzed by Western blotting with anti-HA. As expected, 
both HA-Vpr and HA-RPA32 specifically bound to GST-
UNG2 but not to GST, when they are expressed alone 
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or in combination (Fig.  1a). Similarly, both HA-Vpr 
and HA-UNG2 were able to bind to GST-RPA32 when 
they were expressed in combination (Fig.  1b). However, 
HA-Vpr expressed alone did not bind to GST-RPA32 
(Fig. 1b), indicating that UNG2 acts as a linker between 
RPA32 and Vpr to form a trimolecular complex contain-
ing Vpr, UNG2 and RPA32, as schematized on Fig.  1d. 
Finally, we demonstrated that endogenous UNG2 and 
RPA32 proteins could associate together with HA-Vpr 
by a co-immunoprecipitation assay. HA-Vpr expressing 
cells were lysed and Vpr was immunoprecipitated with 
an anti-HA antibody. As shown in Fig.  1c, endogenous 
UNG2 and RPA32 were detected only in the precipi-
tate from lysate of cells expressing HA-Vpr but not from 
mock cell lysate.
UNG2 and RPA32 are required for efficient HIV‑1 
replication in established human cell lines
First, we analyzed how UNG2 and RPA32 might affect 
virus replication in human established cell-lines. 
Replication-competent viruses were produced in 293T 
cells depleted of UNG2 or RPA32 with specific shRNAs, 
and used to infect target HeLa-CD4 cells also depleted for 
UNG2 or RPA32 with the same shRNAs. As evidenced 
by Western blot analysis of cell lysates from shRNA-
transduced 293T and HeLa-CD4 cells (Fig.  2a, left and 
right panels, respectively), the UNG2 protein bands of 
37–39 kDa as well as the RPA32 protein band of 32 kDa 
were significantly reduced in lysates from shUNG2- or 
shRPA32-transduced cells but not from shLuc-trans-
duced control cells. Moreover, we also noticed an impor-
tant decrease of the 70 kDa subunit (RPA70) expression 
in shRPA32-transduced cells suggesting a destabiliza-
tion of the whole RPA complex through depletion of the 
RPA32 subunit (Fig. 2a, lower panels).
As shown in Fig. 2b, c, the depletion of UNG2 in HeLa-
CD4 cells led to a drastic decrease of virus replication 
as measured by the concentration of the viral p24 cap-
sid protein (p24) in the cell-culture supernatant. This 
impairment in virus replication in shUNG2-transduced 
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Fig. 1 Characterization of the Vpr/UNG2/RPA32 molecular complex. a, b In vitro binding analyses of Vpr/UNG2/RPA32 interactions. 293T cells were 
cotransfected with plasmids for expression of HA‑tagged forms of Vpr, UNG2 and RPA32. Lysates from transfected cells were then incubated with 
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HeLa-CD4 cells (red curve and red bars, respectively) 
was observed as soon as 2  days post-infection and 
remained significant 4 and 8  days post-infection com-
pared to shLuc-transduced HeLa-CD4 control cells 
(black curve and black bars). The requirement of the 
RPA32 protein for HIV-1 replication in HeLa-CD4 cells 
was similarly analyzed (Fig.  2b, c). Compared to con-
trol viruses produced in shLuc-transduced 293T cells 
and used to infect shLuc-transduced control HeLa-CD4 
cells (black curve and black bars), viruses produced in 
RPA32-depleted cells also failed to replicate efficiently 
in RPA32-depleted HeLa-CD4 target cells (green curve 
and green bars). Together, these results clearly show 
the requirement of UNG2 and RPA32 proteins in both 
producing and target cells to ensure efficient virus rep-
lication. Furthermore, as previously reported [7], a 
significant decrease in virus infectivity, evaluated in a 
single-round infection assay with non-replicative GFP 
reporter viruses, was observed when viruses were pro-
duced in UNG2- and RPA32-depleted HeLa-CD4 cells 
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(Fig.  2d), suggesting that incorporation of UNG2 and 
RPA32 into viral particles is required for maintaining full 
HIV-1 infectivity in this single-round infection assay. In 
order to confirm that the defect in virus replication in 
UNG2- and RPA32-depleted cells was related to a defect 
in the reverse transcription (RT) process, total viral DNA 
reverse transcripts were quantified 7 h after infection of 
HeLa-CD4 cells. As shown in Fig. 2e, a significant reduc-
tion in viral DNA synthesis was observed in UNG2- (red 
bar) and RPA32-depleted (green bar) cells compared to 
shLuc-transduced control cells (black bar).
The requirement of UNG2 and RPA32 for virus rep-
lication was then analyzed in Jurkat lymphoid T cells 
(Fig.  3). Viruses were produced in UNG2- or RPA32-
depleted 293T cells and used for infection of Jurkat cells 
also depleted of either UNG2 or RPA32 (Fig. 3a). Of note, 
no apparent impact on cell proliferation and viability 
was observed in shUNG2- and shRPA32-tranduced cells 
(data not shown). As shown in Fig. 3b, d, the depletion of 
UNG2 in virus producing cells and target Jurkat T cells 
resulted in a net decrease of virus replication (red curve 
and red bars). Interestingly, both viruses produced in 
shLuc- or in shUNG2-transduced cells failed to replicate 
in UNG2-depleted Jurkat recipient cells (red dashed line 
and red slanted oblique bars), indicating that the absence 
of UNG2 expression is critical during several rounds of 
virus replication and dissemination in the target Jur-
kat T cells. In agreement, depletion of UNG2 in virus-
producing cells only was not sufficient to impact virus 
replication in Jurkat control cells (black dashed line and 
black slanted oblique bars). Similarly, viruses produced in 
RPA32-depleted cells or shLuc-transduced cells failed to 
replicate efficiently in RPA32-depleted Jurkat target cells 
(Fig. 3c, e). Like in HeLa-CD4 cells, a significant decrease 
in virus infectivity measured in a single-round infec-
tion assay in target Jurkat cells was observed only when 
viruses were produced in UNG2- and RPA32-depleted 
cells (Fig.  3f ), confirming that incorporation of UNG2 
and RPA32 into viral particles is required for maintain-
ing full HIV-1 infectivity in a single-round assay (7). In 
contrast, depletion of UNG2 and RPA32 in the tar-
get Jurkat cells had no effect on virus infectivity in this 
assay (Fig.  3f ), confirming that the absence of UNG2 
and RPA32 is only critical during several rounds of virus 
replication. These results confirm the positive impact 
of UNG2 and RPA32 for efficient HIV-1 replication in 
human cell-lines.
UNG2 and RPA32 are expressed at low level in HIV‑1 
primary target cells
Because most of the studies regarding the potential role 
of UNG2 for HIV-1 infectivity and replication have been 
performed using established human cell-lines [7, 10, 12, 
29], we then focused our study on the impact of endog-
enous UNG2 as well as RPA32 in the context of primary 
target cells of HIV-1, including PBMCs and macrophages 
isolated from blood of healthy donors. First, we ana-
lyzed UNG2 and RPA32 expression in human cell lines, 
primary monocytes, monocyte-derived macrophages 
(MDMs), as well as activated and non-activated PBMCs 
both at the protein and mRNA transcript levels. As evi-
denced by Western blot analysis (Fig. 4a), all the primary 
cells studied expressed very low or undetectable levels 
of UNG2 compared to different cell lines such as 293T, 
HeLa-CD4 cells and the Jurkat CD4 T-lymphoid cell-line. 
In PBMCs (middle panels), different donors were ana-
lyzed and a variability in protein expression was observed. 
We failed to detect a UNG2 band in cells from two differ-
ent donors (donors 1 and 2) whereas a band correspond-
ing to the 39  kDa UNG2 protein was observed from 
one donor (donor 3). Similarly, quantification of UNG2 
mRNA evaluated by semi-quantitative qRT-PCR on 
the same primary cells and cell-lines confirmed the low 
level of UNG2 transcripts in HIV-1 primary target cells 
(See figure on previous page.) 
Fig. 2 Impact of UNG2 and RPA32 depletion on HIV‑1 replication in HeLa‑CD4 cells. a Depletion of UNG2 and RPA32 in 293T (left panels) and HeLa‑
CD4 (right panels) cells. Cells were transduced with lentiviral vectors expressing shRNA against UNG2, RPA32 or Luciferase (Luc) used as a control. 
Lysates from shRNA‑transduced cells were analyzed by Western blot using anti‑UNG2, anti‑RPA32, anti‑RPA70 and anti‑β‑actin antibodies. b, c Virus 
replication in UNG2‑ or RPA32‑depleted cells. Replication‑competent viruses were produced in UNG2‑, RPA32‑depleted or in control shLuc 293T 
cells, normalized for viral p24, and then used for infection of UNG2‑depleted (red line and bars), RPA32‑depleted (green line and bars) or control 
shLuc (black line and bars) HeLa‑CD4 cells. Aliquots of cell culture supernatant were collected 2, 4, and 8 days after infection for p24 quantification. 
In b, the kinetic of replication shown is representative of four independent experiments. In c, results are the means of the four independent experi‑
ments and are expressed as the percentage of p24 production at each time point relative to that of shLuc‑transduced HeLa‑CD4 cells infected with 
control viruses. d Virus infectivity. Wild‑type GFP reporter viruses were produced in shUNG2‑, shRPA32‑ or shLuc‑transduced 293T cells, normalized 
for p24, and then used to infect shUNG2‑, shRPA32‑ or shLuc‑transduced HeLa‑CD4 cells as indicated. The percentage of GFP‑positive infected cells 
was then measured by flow cytometry 60 h later. Viral infectivity was normalized to that of viruses produced in control 293T cells and measured on 
control HeLa‑CD4 as target cells. e Quantification of total viral DNA. Infected HeLa‑CD4 cells were collected 7 h after infection, subjected to DNA 
purification, and the total viral DNA was quantified by qPCR using specific primers for U5‑gag. Results are expressed as the percentage of total viral 
DNA relative to that of shLuc‑transduced HeLa‑CD4 cells infected with control viruses produced in shLuc‑transduced 293T cells. Values are the 
means of at least three independent experiments. Error bars represent 1 SEM (standard error of the mean). Statistical significance was determined 
using Students t test (ns, p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001)
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compared to established human cell-lines (Fig. 4b). How-
ever, low but significant expression of UNG2 transcripts 
was detected, especially in activated PBMCs from the 
three donors and macrophages compared to the negative 
controls (Fig. 4b, inset). Regarding RPA32 expression, the 
protein was also undetectable in myeloid lineages while 
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Fig. 3 Impact of UNG2 and RPA32 on HIV‑1 replication in Jurkat T cells. a Depletion of UNG2 and RPA32 in Jurkat cells. Cells were transduced with 
lentiviral vectors expressing shRNA against UNG2, RPA32 or Luciferase. Lysates from shRNA‑transduced cells were analyzed by Western blot using 
anti‑UNG2, anti‑RPA32, anti‑RPA70 and anti‑β‑actin antibodies. b–e Virus replication in UNG2‑ or RPA32‑depleted Jurkat cells. Replication‑compe‑
tent viruses were produced in UNG2‑ (B and D) or RPA32‑ (c, e) depleted cells or in control shLuc‑transduced 293T cells, normalized for p24, and 
then used for infection of shLuc‑, shUNG2‑ or shRPA32‑transduced Jurkat cells. Aliquots of cell culture supernatant were collected 2, 4, and 8 days 
after infection for p24 quantification. In b, c, the kinetic of replication shown is representative of four independent experiments. In d, e, values are 
the means of the four independent experiments. Results are expressed as the percentage of p24 production at each time point relative to that of 
shLuc‑transduced Jurkat cells infected with viruses produced in shLuc‑transduced 293T cells. f Virus infectivity in UNG2‑ and RPA32‑depleted cells. 
Wild‑type GFP reporter viruses were produced in shUNG2‑, shRPA32‑ or shLuc‑transduced 293T cells, normalized for p24, and then used to infect 
shUNG2‑, shRPA32‑ or shLuc‑transduced Jurkat cells as indicated. The percentage of GFP‑positive infected cells was then measured by flow cytom‑
etry 60 h later. Viral infectivity was normalized to that of viruses produced in shLuc‑transduced 293T cells and measured on shLuc‑transduced Jurkat 
as target cells. Error bars represent the SEM. Statistical significance was determined by using the Students t test (ns, p > 0.05; *p < 0.05; **p < 0.01)
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it was highly expressed in cell lines (Fig. 4a). In PBMCs 
depleted of the myeloid cells but containing the lymphoid 
cells, RPA32 was again detected from the cells of donor 
3, where the protein is well expressed. In cells of donor 2, 
RPA32 protein was only weakly detected in cells activated 
with PHA and IL-2. For both donors 2 and 3, we noticed 
that activated PBMCs displayed more RPA32 protein 
expression than non-activated cells. qRT-PCR analysis of 
RPA32 mRNA content in cell lines as well as in primary 
cells confirmed that the RPA32 gene is less weakly tran-
scribed in PBMCs, especially when cells were activated, 
compared to myeloid cells (Fig. 4c). However, the RPA32 
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transcript level remains very low compared to the 293T, 
HeLa and Jurkat cell lines. These results confirm that 
UNG2 and RPA32, two cellular proteins involved in DNA 
repair and replication, are expressed at lower levels in 
primary lymphoid and myeloid cells than in established 
cell lines.
Impact of UNG2 and RPA32 on HIV‑1 replication in PBMCs
According to these observations, it seemed important to 
reevaluate the contribution of both UNG2 and RPA32 
proteins on virus replication in the primary target cells 
of HIV-1. First, the replication of viruses produced in 
UNG2- and RPA32-depleted cells was then analyzed in 
PBMCs. X4-tropic viruses (NL4.3 strain) were produced 
in UNG2- or RPA32-depleted cells as well as in control 
cells and used to infect PBMCs isolated from different 
blood donors. As shown in Fig. 5a (red curves), depletion 
of UNG2 in virus-producing cells negatively impacted 
virus replication in PBMCs from the five donors. Sum-
mary and statistical analysis of the replication data meas-
ured for the different donors are shown in Fig.  5b. We 
observed a significant decrease of p24 production (about 
50 %) when PBMCs were infected with viruses produced 
in UNG2-depleted cells. This defect in virus replication 
and production was evidenced as early as 2  days after 
infection and remained significant after 8  days (Fig.  5b, 
red bars), suggesting that the low level of UNG2 and 
RPA32 is not sufficient to restore long term efficient virus 
replication in PBMCs. In parallel, we analyzed the impact 
of RPA32 depletion during virus replication in PBMCs 
from the same donors. As shown in Fig.  5a (green 
curves), viruses produced in RPA32-depleted cells exhib-
ited differential replication abilities depending on the cell 
donor. Compared to control viruses (black curves), a rel-
ative defect in virus replication was observed in PBMCs 
from three out of five donors (donors 1, 2 and 4), while 
replication in PBMCs from donors 3 and 5 was similar to 
that of the control viruses. Although a slight decrease of 
p24 production was continuously observed from viruses 
produced in RPA32-depleted cells during the 8  days 
of monitoring (Fig.  5b, green bars), this defect in virus 
replication was not statistically significant compared to 
the control viruses (black bars). These data regarding the 
role of RPA32 for HIV-1 replication could be linked to 
the differential level of protein expression measured in 
PBMCs from individual donors (see Fig. 4).
Since we previously showed that the defect of virus 
replication in UNG2-depleted human CD4-positive 
cell lines ([7], Fig. 2e) was related to a defect in the RT 
process, we quantified total viral DNA reverse tran-
scripts 7  h after infection of PBMCs with viruses pro-
duced in UNG2- or RPA32-depleted cells. As shown in 
Fig.  5c, a significant reduction of the total viral DNA 
was observed with viruses produced in UNG2-depleted 
cells (red bar) compared to viruses produced in control 
cells (black bar). Interestingly, a slight but significant 
decrease in viral DNA synthesis was also revealed when 
PBMCs were infected with viruses produced in RPA32-
depleted cells (Fig. 5c, green bar). Together, these results 
confirm that UNG2 and RPA32 depletion negatively 
impacted virus replication in PBMCs by influencing 
the efficiency of the RT process. Again, production in 
UNG2- or RPA32-depleted cells had a negative impact 
on virus infectivity measured in a single-round infection 
assay using PBMCs as target cells (Fig.  5d) confirming 
the requirement for UNG2 and RPA32 for optimal virus 
infectivity.
UNG2 and RPA32 enhances HIV‑1 replication 
in macrophages
Besides the CD4-positive T-cell population, mac-
rophages are thought to be important in the persistence 
and pathogenesis of HIV-1 infection due to their wide-
spread presence in various tissues and their contribution 
to long-lived reservoirs of virus-infected cells [2, 3]. We 
therefore investigated the replication of viruses produced 
in UNG2- or RPA32-depleted cells in macrophages. 
These cells also express low levels of UNG2 and RPA32 
(see Fig.  4). R5-tropic viruses (YU-2 strain) were pro-
duced in UNG2- or RPA32-depleted cells and used to 
infect MDMs from different healthy donors. As shown 
in Fig. 6a, UNG2- (red curves) but also RPA32-depleted 
(See figure on previous page.) 
Fig. 4 UNG2 and RPA32 expression in human cell lines and primary cells. Primary monocytes and PBMCs were isolated from blood of healthy 
donors. While PBMCs were activated in culture medium supplemented with PHA for 72 h and then IL‑2 for 48 h, monocytes were differentiated in 
macrophages for 7 days in culture medium supplemented with M‑CSF. a UNG2 and RPA32 protein expression. Equivalent amounts of proteins from 
total lysates of 293T, HeLa‑CD4 and Jurkat cells, monocytes and macrophages, and non‑activated and activated PBMCs (NA and A, respectively) 
were resolved by SDS‑PAGE and analyzed by Western blotting with anti‑UNG, anti‑RPA32 and anti‑β‑actin antibodies. b, c Quantification of UNG2 
and RPA32 mRNA expression. RNA was extracted and purified from 293T, HeLa‑CD4, Jurkat cells, monocytes, macrophages, and non‑activated and 
activated PBMCs, and UNG2 (b) and RPA32 (c) mRNA expression levels were then measured by quantitative RT‑qPCR. Results are expressed as the 
percentage of UNG2 and RPA32 mRNA copies relative to those measured from 293T cell RNA extract. Data shown are means of three independent 
experiments (293T, HeLa and Jurkat cells) or from three independent donors for PBMCs and MDMs, performed in duplicate. Error bars represent 1 
standard deviation (SD) from the mean. The inset graphs focus on mRNA expression levels in the primary cells. Negative control corresponds to 293T 
RNA extract processed without reverse transcriptase in the reaction mixture. ND no detection
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(green curves) virions failed to replicate efficiently in 
MDMs isolated from three blood donors. Compared to 
the p24 production monitored 4 and 8  days after infec-
tion of MDMs with control wild-type viruses (Fig.  6c, 
black bars), the p24 production from MDMs infected 
with UNG2- or RPA32-depleted viruses was significantly 
reduced (50–70  %) (red and green bars, respectively). 
Previously, we and others clearly showed that UNG2 is 
incorporated into virions through direct interaction with 
the viral Vpr protein (6–12), we similarly analyzed repli-
cation in MDMs of vpr-deleted viruses (ΔVpr) produced 
from UNG2- and RPA32-depleted cells (Fig.  6b, c). In 
contrast to wild-type viruses, no significant difference in 
viral replication was detected between ΔVpr viruses pro-
duced in control cells and UNG2- and RPA32-depleted 
ΔVpr viruses. These results indicate that the recruitment 
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Fig. 5 Impact of UNG2 and RPA32 on HIV‑1 replication in PBMCs. a–c Viral replication. Replication‑competent viruses were produced in shLuc‑ 
(black curves and bars), shUNG2‑ (red curves and bars) or shRPA32‑ (green curves and bars) transduced 293T cells, normalized for p24, and then used 
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after infection for p24 quantification. In a, the individual kinetics of replication in PBMCs from the five healthy donors are shown. In b, results are 
expressed as the percentage of p24 production at each time point relative to that of PBMCs infected with viruses produced in shLuc‑transduced 
(black bars) 293T cells. Values are the means of two independent experiments performed on PBMCs from the five healthy donors. In c, PBMCs were 
collected 7 h after infection, subjected to DNA purification, and total viral DNA was quantified via qPCR using specific primers for U5‑gag. Results are 
expressed as the percentage of total viral DNA relative to that of PBMCs infected with viruses produced in shLuc‑transduced (black bar) cells. d Virus 
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Viral infectivity was normalized to that of viruses produced in shLuc‑transduced 293T cells. Error bars represent the SEM. Statistical significance was 
determined by using the Students t test (ns, p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001)
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of UNG2 and RPA32 into virions favors virus dissemi-
nation in differentiated macrophages which express low 
levels of these two cellular proteins. Moreover, these 
cells could not counteract the negative effect of UNG2 
depletion in the initial 293T cells. In agreement, infec-
tivity of single-round viruses produced in UNG2- or 
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RPA32-depleted cells was also impaired using MDMs as 
target cells (Fig. 6d).
As previously, we further investigated whether the 
impairment of replication in MDMs of UNG2- or 
-RPA32-depleted viruses was also linked to a RT defect 
during the establishment of infection. The total viral 
DNA reverse transcripts were measured 72  h after 
infection of MDMs with viruses produced from UNG2- 
or RPA32-depleted cells, and revealed a reduction of 
about 50–60  % of the total viral DNA synthesis com-
pared to MDMs infected with control viruses (Fig.  6e). 
As observed in PBMCs, the absence of either UNG2 
or RPA32 expression in virus-producing cells similarly 
decreases the efficiency of the RT process during viral 
replication in MDMs.
Finally, replication of viruses produced from cells 
depleted of both endogenous UNG2 and RPA32 pro-
teins was evaluated in MDMs. 293T cells were thus co-
transduced with two lentiviral vectors expressing specific 
shRNAs targeting UNG2 and RPA32, leading to efficient 
depletion of both proteins as evidenced by Western blot 
analysis (Fig.  6f ). Replication-competent virus particles 
were produced in these double-depleted cells and used 
to challenge MDMs as previously. As shown in Fig.  6g, 
the replication impairment of viruses produced in cells 
depleted of both proteins (slanted red/green bar) was 
similar to the replication defect measured in MDMs 
infected with viruses produced in cells depleted of UNG2 
only (red bar). The p24 concentration in MDM super-
natant was indeed reduced of about 40–50  % for both 
viruses produced in shUNG2- or in shUNG2/shRPA32-
tranduced cells 8 days after infection, showing that simul-
taneous depletion of UNG2 and RPA32 had no additional 
or synergistic effects compared to viruses produced in 
UNG2-depleted cells.
UNG2 impacts on HIV‑1 dissemination between T cells 
and macrophages
Because macrophages express low levels of both UNG2 
and RPA32 proteins, we developed experimental systems 
to analyze how UNG2 and RPA32 expression could influ-
ence cell-free virus dissemination from T lymphocytes 
to macrophages or, reciprocally, from macrophages to T 
lymphocytes.
First, we analyzed virus dissemination from T cells 
to MDMs as schematized in Fig.  7a, using UNG2- and 
RPA32-depleted Jurkat T cells as virus producing cells 
and MDMs expressing low or undetectable levels of 
UNG2 protein as target cells. Briefly, Jurkat cells were 
first transduced with shRNA targeting UNG2 or RPA32 
and then infected with replication-competent HIV-1 
co-expressing the vesicular stomatitis virus G (VSV-G) 
envelope to standardize the level of infected Jurkat cells. 
Three days later, virus particles were collected from the 
cell culture supernatant from shUNG2- or shRPA32-
transduced Jurkat cells, normalized for viral p24, and 
used to infect MDMs. Virus replication in the target 
MDMs was measured 4 and 8  days later by monitoring 
p24 content in the cell culture supernatants. Three inde-
pendent experiments using recipient MDMs from three 
different donors were performed in duplicate (Fig.  7b), 
and the replication data measured for the three donors 
is summarized in Fig. 7c. As expected, UNG2 depletion 
in virus-producing Jurkat T cells impaired virus dis-
semination in MDMs (red curves and bars). This impair-
ment in virus replication was equivalent to the defect 
(See figure on previous page.) 
Fig. 6 Impact of UNG2 and RPA32 on HIV‑1 replication in macrophages. a–c Wild‑type (a) or Δvpr (b) replication‑competent viruses were produced 
in shLuc‑ (black curves and bars), shUNG2‑ (red curves and bars) or shRPA32‑ (green curves and bars) transduced 293T cells, normalized for p24, and 
then used for infection in duplicate of MDMs from 3 different healthy donors. In a and b, aliquots of MDM cell culture supernatants were collected 4 
and 8 days after infection for p24 quantification. The individual kinetics of replication in PBMCs from the three healthy donors are shown. In c, results 
are expressed as the percentage of p24 production at each time point relative to that of MDMs infected with wt or Δvpr viruses produced in shLuc‑
transduced (black bars) cells. Values are the means of two independent experiments performed on MDMs from the two donors. d Virus infectivity 
in MDMs. Wild‑type GFP reporter viruses were produced in shUNG2‑, shRPA32‑ or shLuc‑transduced 293T cells, normalized for p24, and then used 
to infect MDMs from three different donors. The percentages of GFP‑positive infected cells were then measured by flow cytometry 60 h later. Viral 
infectivity was normalized to that of viruses produced in shLuc‑transduced (black bars) 293T cells. e Replication‑competent viruses were produced 
in shLuc‑, shUNG2‑ or shRRA32‑transduced 293T cells, normalized for p24, and then used for infection of MDMs from three different donors. MDM 
samples were collected 72 h after infection, subjected to DNA purification, and total viral DNA was quantified via qPCR using specific primers for U5‑
gag. Results are expressed as the percentage of total viral DNA relative to that of MDMs infected with viruses produced in shLuc‑transduced (black 
bar) cells. f Double‑depletion of UNG2 and RPA32 expression in virus‑producing 293T cells. Cells were transduced with lentiviral vectors expressing 
shRNA against UNG2 or Luciferase and containing the gene for puromycin resistance, and with lentiviral vectors expressing shRNA against RPA32 or 
Luciferase and the GFP reporter gene. Lysates from shRNA‑transduced cells were analyzed by Western blot using anti‑UNG2, anti‑RPA32 and anti‑
β‑actin antibodies. g Replication‑competent viruses were produced in shLuc/shLuc‑GFP (black bar), in shUNG2/shLuc‑GFP (red bar) or in shUNG2/
shRPA32‑GFP (red and green hatched bar) 293T cells, normalized for p24, and then used for infection of MDMs from three different healthy donors. 
The concentration of p24 after 8 days of infection was expressed as the percentage of p24 production relative to that of MDMs infected with 
viruses produced in shLuc‑transduced (black bar) cells. Error bars represent the SEM. Statistical significance was determined using Students t test (ns, 
p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001)
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three different donors of viruses produced in shUNG2‑ or shRPA32‑tranduced Jurkat cells are shown. In c, results are expressed as the percentage of 
p24 production at each time point relative to that of MDM cells infected with control viruses. Values are the means of two independent experi‑
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we previously observed in MDMs infected with viruses 
produced in UNG2-depleted 293T cells (see Fig.  6a, c). 
Surprisingly, depletion of RPA32 in virus-producing Jur-
kat T cells had no significant effect on virus replication 
in MDM recipient cells from the same donors (Fig.  7b, 
c, green curves and bars), suggesting that RPA32 is not 
required for virus dissemination specifically from Jurkat 
T cells toward macrophages.
Finally, dissemination of cell-free virus particles from 
macrophages toward T cells was analyzed using infected 
MDMs as virus-producing cells and UNG2- or RPA32-
depleted Jurkat cells as target cells (schematized in 
Fig.  8a). MDMs were infected with replication-compe-
tent HIV-1 co-expressing the VSV-G envelope to increase 
and standardize the level of infected MDMs. After 8 days 
of infection, virus particles produced were collected 
from the MDM cell culture supernatant, normalized for 
p24 and used to infect Jurkat T cells previously trans-
duced with shRNA targeting UNG2 or RPA32, as well 
as shLuc-transduced Jurkat cells as control cells. Viral 
replication was finally assessed in these recipient Jurkat 
cells by p24 monitoring in the cell culture supernatants at 
different days after infection. Independent experiments 
using viruses produced from MDMs isolated from five 
different donors were performed in duplicate (Fig.  8b), 
and the replication data measured for all the donors are 
summarized in Fig. 8c. Clearly, virus particles produced 
from macrophages replicated in control Jurkat cells, 
whereas replication of the same viruses in UNG2- or 
RPA32-depleted cells was severely affected (Fig.  8b). As 
summarized in Fig. 8c, virus production from shUNG2- 
or shRPA32-transduced Jurkat target cells led to an ini-
tial slight decrease of virus production measured 2 days 
after infection, but a 70–90 % decrease from UNG2- and 
RPA32-depleted T cells was measured 4 and 8 days after 
infection. These data confirm the positive impact of 
UNG2 and RPA32 for the long term replication of HIV-1 
in target T cells.
Taken together, these results indicate that UNG2 is 
required for optimal replication and dissemination of 
cell-free virus particles between the target cells of HIV-
1, while RPA32 is only required for dissemination from 
MDMs to target T cells.
Discussion
We previously documented that incorporation of the 
UNG2 DNA repair protein into virus particles was 
required for modulation of the reverse transcription 
process [6, 30] resulting in a positive effect on HIV-1 
infectivity and replication in established cell-lines [7]. 
However, this positive impact of UNG2 on reverse tran-
scription and virus replication was independent of the 
enzymatic activity of the UNG2 protein. Here, we report 
results showing that the HIV-1 Vpr protein can form a 
complex with UNG2 and the RPA32 subunit of the RPA 
complex in virus-producing cells, and participate in the 
modulation of the reverse transcription process for opti-
mal virus replication and dissemination between the dif-
ferent target cells of HIV-1.
While several previous studies showed that UNG2 was 
efficiently recruited into HIV-1 virions [8–10, 12] indicat-
ing that this recruitment had a positive influence on viral 
replication [8, 9], the role of UNG2 incorporation was 
challenged by other studies, suggesting a dispensable [10, 
29] or detrimental [11, 12, 31] effect of UNG2 on virus 
replication. Because all the previous studies regarding a 
detrimental or dispensable role of UNG2 in HIV-1 repli-
cation have been performed using established human cell-
lines, we investigated and analyzed here the role of UNG2, 
and also RPA32, on virus replication and dissemination 
in HIV-1 primary target cells. In agreement with previ-
ous reports [8, 9, 32, 33], our data confirm the low levels 
of UNG2 and RPA32 expression in primary hematopoietic 
cells including PBMCs and MDMs, both at the protein and 
mRNA transcript levels, compared to established human 
cell-lines. Recent biochemical analyses performed in pri-
mary cells also confirmed that CD4-positive T cells and 
MDMs expressed modest and low levels of UNG activ-
ity, respectively [33]. While the UNG2 and RPA32 pro-
teins were not detectable in MDMs, expression in PBMCs 
seemed more variable and certainly higher than in MDMs. 
However, low but significant levels of UNG2 and RPA32 
mRNAs were detected both in PBMCs and MDMs.
We now highlighted that UNG2 and RPA32 facili-
tated efficient virus replication and dissemination in 
PBMCs and macrophages. In these primary cells, the 
low level of UNG2 and RPA32 proteins did not allow 
the viruses to restore an efficient potential of replica-
tion. It was previously shown by Priet et al. [8] and Jones 
et al. [9] that UNG2 was required for efficient infection 
of macrophages with R5 viruses, but our data indicate 
that both X4 and R5 viruses replicated more efficiently 
in PBMCs and macrophages, respectively, when UNG2, 
and also RPA32, were expressed in virus-producing 
cells. These more efficient virus replication and dissemi-
nation were linked to a specific role of both UNG2 and 
RPA32 on reverse transcription, since we show here that 
a significant defect in the total viral DNA synthesis was 
systematically evidenced in these primary target cells 
when viruses were produced from UNG2- and RPA32-
depleted cells. In addition, similar impairment of virus 
replication in macrophages was observed for viruses 
produced in cells simultaneously depleted of both cellu-
lar proteins, suggesting that these two proteins act in the 
same pathway for the control of HIV-1 replication and 
dissemination.
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Differentiated macrophages residing in different host 
tissues, including the CNS and lymphoid tissues, are 
long-lived cell targets for productive viral replication. In 
order to analyze how UNG2 and RPA32 may influence 
dissemination of cell-free HIV-1 particles between mac-
rophages and T lymphocytes, we developed experimental 
systems to show that viruses produced in macrophages, 
expressing low levels of UNG2 and RPA32, failed to rep-
licate efficiently in UNG2- or RPA32-depleted Jurkat 
T cells. Similarly, viruses produced in UNG2-depleted 
Jurkat T cells did not replicate efficiently in MDMs con-
firming the positive role of UNG2 for dissemination of 
X4- and R5-tropic strains [8, 9]. While we failed to obtain 
substantial and sustain depletion of UNG2 and RPA32 
in either MDMs or PBMCs in order to analyze their role 
for virus dissemination between HIV-1 primary target 
cells, our results suggest that UNG2 and RPA32, depend-
ing of the activation status of PBMCs and MDMs, may 
modulate virus spreading from and toward macrophages 
through positive regulation of the reverse transcription 
process. These observations suggest that UNG2 and 
RPA32 can thus contribute to virus dissemination and 
establishment of persistent reservoirs of virus-infected 
MDMs in different host tissues during the natural course 
of HIV-1 infection ([1], for review).
The determinants of UNG2 required for direct interac-
tion with RPA32 [16, 18, 19, 34] are located in the same 
N-terminal region that the determinants involved in the 
modulation of the viral DNA mutation frequency [7]. 
Since Vpr interacts directly with UNG2 through recogni-
tion of a WxxF motif found in the C-terminal part of the 
protein [6, 35], UNG2 might thus recruit Vpr and RPA32 
simultaneously in a trimolecular complex (see Fig. 1d), as 
evidenced here in  vitro using recombinant proteins but 
also with endogenous cellular proteins by co-immuno-
precipitation assay. In addition, it would be interesting 
to analyze whether the two other subunits of RPA (i.e., 
RPA70 and RPA14) could also be recruited together with 
RPA32 in this complex.
The RPA complex plays key roles in different DNA 
repair pathways such as repair of DNA double-strand 
breaks by homologous recombination [36, 37] during 
post-replicative base excision repair (BER) in association 
with UNG2 [34, 38]. As a ssDNA binding protein, RPA32 
is directly involved in the control of the assembly of the 
DNA repair machinery when DNA damage pathway 
signaling is engaged [39, 40]. Both RPA32 and UNG2 are 
thus present in the same replication foci [34], where the 
RPA complex recruits and enhances the ability of UNG2 
to remove uracil in ssDNA at the replication fork [16, 18, 
19, 34]. A similar involvement of both UNG2 and RPA32 
proteins for efficient removal of uracil residues during 
viral DNA synthesis in primary HIV-1 target cells could 
be postulated. However, we previously showed that this 
positive impact of UNG2 on reverse transcription was 
related to a non-canonical scaffolding mechanism inde-
pendent of the catalytic activity of the enzyme [7]. Inter-
estingly, several reports accumulated evidences for such a 
scaffolding nonenzymatic role of UNG2 and viral-related 
UNG proteins. While UNG2 is absolutely required for 
efficient CSR and controlled SHM processes in B lym-
phocytes, controversial results showing that the enzy-
matic removal activity of the protein is dispensable for 
these activities [23, 24, 26, 41, 42]. It was suggested that 
the N-terminal domain of UNG2 may recognize DNA 
double-strand breaks and acts as an accessory site to pro-
vide a structural support for a scaffold function of the 
protein [27, 43]. Such a scaffolding function of UNG2, 
independent of its enzymatic activity but related to the 
N-terminal part of the protein, was also highlighted by its 
role during the assembly of the human centromere pro-
tein A (CENP-A) to sites of DNA damage [44]. Interest-
ingly, CSR and assembly of CENP-A are both inhibited by 
ectopic expression of the wild-type HIV-1 Vpr protein via 
direct interaction with UNG2 suggesting that UNG2 may 
be recruited or act through its WxxF motif during these 
processes [26, 44].
Furthermore, UNG proteins encoded by numer-
ous viruses, such as Poxviridae and Herpesviridae, are 
required for efficient virus replication in their respec-
tive primary target cells through a mechanism inde-
pendent of the uracil-excising activity of their UNG 
protein [45–48]. For example, it was recently showed 
that the BKRF3 UNG protein encoded by Epstein–Barr 
virus played a critical role in the viral DNA synthe-
sis by recruiting cellular and viral proteins to replica-
tion sites, but this function was also independent of 
its enzymatic activity [49]. While we cannot formally 
exclude that UNG2 also acts on the HIV-1 reverse tran-
scription process through an enzymatic-dependent 
mechanism, our results highlight a potential scaffolding 
role of UNG2 related to RPA32 binding. This nonenzy-
matic scaffolding function of cellular UNG2 would be 
important during HIV-1 dissemination. Nonetheless, 
further investigations should give access to the char-
acterization of this novel role of UNG-related proteins 
in various biological activities such as CSR and SHM 
processes in B lymphocytes as well as DNA synthesis of 
several viruses, including HIV-1.
Our results strongly suggest that UNG2 acts as a 
scaffold protein recruiting RPA32 into virions and that 
this interaction is required during the UNG2-depend-
ent mechanism of RT control. Interestingly, it was 
very well documented that the RPA trimeric complex 
directly participated and played a crucial role in DNA 
replication of the simian virus 40 (SV40) and other 
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polyomaviruses ([22], for review). More recent reports 
showed that this protein complex was also involved, 
indirectly or directly through viral DNA binding, in 
DNA synthesis of numerous other viruses, including 
Eptein Barr and Herpes simplex herpesviridae, adeno-
virus as well as polyoma- and papillomaviruses [45–
48, 50–52]. During SV40 replication, RPA must act 
at different steps including the opening of the double 
strand DNA and the stabilization of the single strand 
DNA [22]. Although the exact mechanism of the RPA 
complex during the HIV-1 DNA synthesis needs to be 
specifically determined, we can hypothesize that RPA 
allows both (1) for efficient recruitment and processiv-
ity of the viral RT, and (2) for protection of the single 
strand viral DNA from degradation by direct binding. 
Indeed, it was also reported that the RPA complex was 
able to inhibit the deamination activity and the pro-
cessivity of the APOBEC3G cytidine deaminase, sug-
gesting that RPA plays a role in DNA protection from 
the editing activity of APOBEC3 proteins [53]. This 
last observation could support a model in which the 
recruitment of RPA32 by Vpr and UNG2 at the site of 
RT leads to the binding of RPA32 to the negative viral 
DNA for protection from deamination and nuclease 
activities. However, this protective role of RPA32, par-
ticularly against APOBEC3G activity, has to be more 
explored and might explain why the presence of Vpr 
can limit the APOBEC3G effect as reported before 
[11]. In agreement with a role of the RPA32 subunit 
of the RPA trimeric complex in HIV-1 DNA synthe-
sis and viral replication, it was also previously shown 
that the RPA complex had a positive impact, at least 
in  vitro, on the efficiency of the HIV-1 reverse tran-
scription [54, 55].
Conclusions
The results reported here indicate that cellular UNG2 
and RPA32 facilitate optimal virus replication and dis-
semination in PBMCs and macrophages through positive 
modulation of the reverse transcription process. Interest-
ingly, and in favor of a positive impact of the endogenous 
UNG2 for virus replication, it has been recently shown 
that the DNA synthesis of the human hepatitis B virus 
(HBV) was also facilitated in a UNG2-dependent man-
ner in primary hepatocytes [56, 57]. In this model, UNG2 
may counteract APOBEC-induced hypermutation of the 
HBV genome. Similarly, our results argue for a positive 
role of UNG2 and RPA for optimal viral DNA synthesis 
and virus dissemination between the primary target cells 
of HIV-1. These cellular proteins may thus contribute to 
virus dissemination and the establishment of viral reser-
voirs in different host tissues during the natural course of 
HIV-1 infection.
Methods
Vectors and expression plasmids
Vectors for expression of the HA-tagged forms of the 
wild-type UNG2 and Vpr proteins have been described 
previously [7, 58]. For the plasmid encoding HA-tagged 
RPA32, the RPA32 coding sequence was amplified by 
PCR with specific primers from the pGAD-RPA32 plas-
mid described previously [19], and the PCR product was 
then subcloned into the BamHI and XhoI restriction sites 
of the pAS1B plasmid as described [6]. The plasmid for 
expression in bacteria of UNG2 fused to GST has been 
described previously [6], while the plasmid encoding for 
GST-RPA32 (pGEX4T1-GST-RPA32) has been kindly 
provided by Yuan Jingsong from the University of Texas 
(USA). The pLKO.1 lentiviral vectors containing the gene 
for puromycine resistance and harboring shRNA target-
ing UNG2, RPA32 or the firefly luciferase (Luc) control 
were purchased from Sigma and have been described 
[7]. The pLKO.1-shLuc-GFP, and the pLKO.1-shRPA32-
GFP vectors were constructed by replacing the puromy-
cin resistance gene by the GFP reporter gene between 
the BamHI and the KpnI restriction sites of the paren-
tal pLKO.1-shUNG2 and -shRPA32 vectors [7]. The 
infectious clones of the NL4.3 and YU2 HIV-1 isolates 
(pNL4.3 and pYU2), as well as the plasmid encoding the 
VSV-G envelope glycoprotein, have been described [6, 7, 
30].
Cell culture and transfection
Jurkat T cells were maintained in Roswell Park Memo-
rial Institute Medium (RPMI) while 293T cells and HeLa 
cells stably expressing CD4 (HeLa-CD4 cells) were grown 
in Dulbecco Minimal Essential Medium supplemented 
with 10  % fetal calf serum (FCS), 100  IU  penicillin/mL 
and 100 µg streptomycin/mL (Invitrogen); shRNA-trans-
duced Jurkat and 293T cells were maintained in complete 
medium containing 1  µg/mL puromycin (Invitrogen). 
Human monocytes and PBMCs were isolated from blood 
of healthy volunteers (Etablissement Français du Sang, 
Hôpital Saint-Antoine, Paris, France) by density gradi-
ent sedimentation in Ficoll (GE Healthcare) followed 
by adhesion-selection for 2  h at 37  °C. After extensive 
washing, monocytes were differentiated in macrophages 
(MDMs) for 10 days in complete culture medium RPMI 
1640 supplemented with 20  % FCS, 100  IU  penicillin/
mL, 100  µg  streptomycin/mL (Invitrogen) and 10  ng/
mL of macrophage colony-stimulating factor (M-CSF) 
(Miltenyi Biotec). For activation of PBMCs, cells were 
grown in complete RPMI medium supplemented with 
phytohemagglutinin (PHA) (5 µg/mL) for 72 h and then 
resuspended in complete medium containing 10  ng/mL 
of IL-2. All cells were grown at 37 °C under 5 % CO2. For 
virus production, immunoprecipitation and pulldown 
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assays, 293T cells were transfected using calcium phos-
phate DNA precipitation technique as described [6, 7, 
59]. For lentiviral vector production, 293T cells were 
transfected using Jet Pei reagent (Polyplus Transfection) 
according to the manufacturer’s instructions.
Pulldown and immunoprecipitation assays, 
and immunoblot analysis
The pulldown assay for analyzing interactions between 
UNG2, RPA32 and Vpr was performed as previously 
described [6, 60]. Briefly, GST-UNG2, GST-RPA32 and 
GST were produced in E. coli, strain BL21, as described 
[60]. 5  µg of recombinant GST, GST-UNG2 or GST-
RPA32 were immobilized on 15  µL of GSH-Sepharose 
beads (GE Healthcare). Beads were washed and then 
incubated with 500  µg of lysate from transfected 293T 
cells as described previously [60, 61]. Bound material 
was resolved by sodium dodecyl sulfate–polyacrylamide 
gel electrophoresis (SDS-PAGE) on 12 % acrylamide pre-
cast gels (BioRad) and then analyzed by Western blotting 
with anti-HA (3F10, Roche) and anti-β-actin (Sigma) 
antibodies.
For immunoprecipitation assay, 293T cells expressing 
HA-Vpr were lysed as described previously [30]. After 
quantification with Bradford (Bio-Rad), 500  µg of cell 
lysate proteins were incubated with 30  µL of anti-HA 
affinity matrice (clone 3F10, Roche) for 2  h under gen-
tle shaking at 4  °C. Elution from beads was carried out 
by incubation in 30  µL of 1× Laemmli buffer contain-
ing DTT for 10 min at 95 °C. 20 µg of the protein lysates 
and 15 µL of the precipitate were then resolved by SDS-
PAGE on 12 % acrylamide precast gels (BioRad). Immu-
noprecipitate and cell lysate proteins were then analyzed 
by Western blotting with anti-HA (3F10, Roche), anti-
UNG2 (clone 2C12, Origene), anti-RPA32 (clone RPA3-
19, Abcam) and anti-β-actin (Sigma) antibodies.
For analysis of endogenous UNG2 and RPA32 expres-
sion in the different cell-lines and primary cells, as well as 
in transduced cells, cells were lysed using a NP40 buffer 
containing a protease inhibitor (Roche) by incubation 
for 30 min on a wheel at 4  °C. After spinning, superna-
tant was collected and the concentration of proteins was 
quantified by Bradford analysis using the manufacturer’s 
protocol (BioRad). Cell lysates were then resolved by 
SDS-PAGE and analyzed by Western blotting using anti-
UNG2 (clone 2C12, Origene), anti-RPA32 (clone RPA3-
19, Abcam) and anti-β-actin (Sigma) antibodies.
Quantification of UNG2 and RPA32 mRNA by qRT‑PCR 
analysis
RNA of cell lines and primary cells was extracted using 
the Pure link RNA mini kit (Ambion) according to man-
ufacturer’s instructions. The reverse transcription was 
performed on equal amount of mRNA using the Max-
ima reverse transcriptase (Thermo Scientific) according 
to the manufacturer’s instructions. The RT reaction was 
processed as follow: 10 min at 25 °C, 15 min at 50 °C and 
5  min at 85  °C. Then, UNG2 and RPA32 cDNAs were 
quantified by the LightCycler 480 qPCR system (Roche 
Applied Science). For UNG2 cDNA amplification, we 
used as forward primer 5′-GCCAGAAGACGCTC-
TACTCC-3′ and as reverse primer 5′-GCATCTC-
CGCTTTCCTCA-3′ which are specific for UNG2 and 
do not amplify UNG1. For RPA32 cDNA amplification, 
we used as forward primer 5′-AGGCCACCTGAGA-
TCTTTTC-3′ and as reverse primer 5′-GGCTTTGCT-
TAGTACCATGTG-3′. Each PCR reaction contains 
1X SYBR Green I Master mix (Roche), 100  nM of each 
primer and 1 µL of the RT product. For absolute quan-
tification, we used dilutions of genomic DNA which 
contains known copies of genome and used as an inter-
nal control. Results were expressed as the percentage of 
UNG2 and RPA32 mRNA copies relative to those meas-
ured from 293T cell RNA extract.
UNG2‑, RPA32‑ and UNG2/RPA32‑depleted cells
VSV-G-pseudotyped lentiviral particles (LVPs) harbor-
ing shRNA targeting Luc (shLuc), UNG2 (shUNG2), 
or RPA32 (shRPA32) were produced in 293T cells as 
described previously [7]. LVPs were then used to trans-
duce 293T, HeLa-CD4 or Jurkat cells, and the levels of 
UNG2 or RPA32 protein expression were assessed by 
Western blot as previously [7]. For double-depletion of 
UNG2 and RPA32, 293T cells were first transduced with 
LVPs harboring the shRNA targeting UNG2 and the 
puromycin resistance gene. After selection in cell cul-
ture medium containing puromycin as described previ-
ously [7], shUNG2-tranduced cells were transduced with 
LVPs harboring the shRNA targeting RPA32 and the GFP 
encoding sequence, and GFP-positive cells were sorted 
72 h later using the BD FACSJAZZ cell sorter.
Virus production, replication and infectivity assays
Replication-competent HIV-1 (NL4.3 or YU2 strains) 
were produced as previously described in shRNA-
transduced 293T cells by transfection with pNL4.3 or 
pYU2 molecular clones [7], and the plasmid for expres-
sion VSV-G was added to the DNA mixture when indi-
cated. For HIV-1 replication monitoring, HeLa-CD4 
cells (2 × 105), Jurkat cells (3 × 105), MDMs (1 × 106) or 
PHA/IL-2-activated PBMCs (2  ×  106) were seeded and 
infected in 6-well plates with 200  ng of viral p24. Cell 
culture supernatants were then collected 2, 4, and 8 days 
after infection (depending on the experiments) for p24 
concentration measurement by enzyme-linked immu-
nosorbent assays (ELISA) as described [7]. To monitor 
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HIV-1 infectivity, single-round-infection viruses carrying 
the GFP gene were produced as previously described [7] 
in shRNA-transduced 293T cells followed by transfection 
with a DNA mix containing the HIV-1-packaging plasmid 
(pCMVDR8.2), the HIV-1 vector encoding GFP (pHIvec2.
GFP), the plasmid encoding the HIV-1 envelope glycopro-
teins of the YU-2 isolate. The supernatant was then col-
lected, filtered, and ultracentrifuged to pellet viruses as 
described previously [7]. For single-round infection exper-
iments, HeLa-CD4 cells (2 × 105), Jurkat cells (3 × 105), 
MDMs (1 × 106) or PHA/IL-2-activated PBMCs (2 × 106) 
were seeded and infected in 6-well plates with 500 ng of 
p24. Cells were cultured at 37  °C for 60  h and samples 
were then fixed in 1 % paraformaldehyde (Sigma-Aldrich) 
and data were collected on a Cytomix FC500 cytometer 
(Beckman-Coulter). The percentage of GFP-positive cells 
was analyzed using the RXP analysis software. Viral infec-
tivity was calculated by normalizing the percentage of 
GFP-positive cells to that obtained in cells infected with 
viruses produced in shLuc-transduced 293T cells.
Quantification of total viral DNA reverse transcripts
One day prior to infection, HeLa-CD4 cells (2  ×  105), 
Jurkat cells (2  ×  105), MDMs (1  ×  106) or activated 
PBMCs (2  ×  106) were plated in 6-well plates. Before 
infection, replication-competent viruses were incubated 
with DNAseI (Roche) for 1  h at 37  °C, and 0.5  µg (or 
1 µg for PBMCs) of p24 was then used for infection. 3 h 
after infection (or 24 h for MDMs), viruses were washed 
off and the cells were subsequently incubated at 37 °C in 
complete medium supplemented with 0.5 µM saquinavir 
in order to restrict viral replication to a single cycle. For 
HeLa-CD4, Jurkat cells and PBMCs, cell samples were 
collected 7 h after infection and DNA was extracted using 
the QIAamp DNA Blood Mini Kit (Qiagen) according to 
the manufacturer’s protocol. For MDMs, DNA extraction 
was carried out 72 h after infection as described [62]. The 
total level of HIV-1 DNA reverse-transcripts was quanti-
fied via the LightCycler 480 qPCR system (Roche Applied 
Science) as previously described [7, 63]. Briefly, the quan-
titative PCR for total HIV-1 DNA was carried out using 
primers targeting the U5-gag region within the HIV-1 
genomic sequence in a 10-µL final volume consisting of 
2X FastStartDNA Tag polymerase (Roche) and 0.3  µM 
of sense MH532 (5′-TGTGTGCCCGTCTGTTGTGT-3′) 
and antisense MH531 (5′-GAGTCCTGCGTCGAGAG 
ATC-3′) primers (TIB MolBiol). The fluorescent probe 
primers 5′-LC640-TCTCTAGCAGT GGCGCCCGAA 
CAG-PH and 5′-CCCTCAGACCCTTTTAGTCAGT 
GTGGAA-FL were used at a concentration of 0.2  µM. 
Total DNA was expressed as copy numbers per cell, with 
the DNA template normalized by β-globin gene amplifi-
cation using a LightCycler control kit DNA (Roche).
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